about pathway bioventures

Pathway Bioventures is an early-stage life sciences fund investing in next-generation therapeutics, medical device, and diagnostics companies. We support extraordinary teams leveraging cutting-edge biotechnology to address major unmet medical needs. Pathway co-invests in early financing rounds within high-quality syndicates.

Beyond our investment, we dedicate ourselves to helping entrepreneurs grow their companies, with specific focus on supporting the seed to Series A transition. We are selective in our investments and put in the effort to build a deep understanding of the technology and its market value. Armed with this knowledge, we become a valuable extension of the early team as we help companies build relationships with future investors and partners.

OUR TEAM

Daniel Jacobs, PhD, MPH

Founder & Managing Director

Daniel founded Pathway Bioventures in 2018 to accelerate the growth of groundbreaking early-stage life sciences companies. He leads Pathway’s operations and investment activities including the identification of new opportunities, diligence, and portfolio company support. A cancer researcher by training, Daniel has expertise in cancer epidemiology, genomics, and RNA therapeutics, having authored or co-authored over 25 peer-reviewed scientific articles and book chapters. He serves as an Entrepreneur-in-Residence at Yale Ventures. Daniel holds an MPH and PhD from Yale University and received post-doctoral training at Baylor College of Medicine.

Matt Martin, PhD, MBA

Venture Partner

As a Venture Partner Matt focuses on sourcing and diligence of investment opportunities for Pathway Bioventures. This work is building on 15 years of management experience from roles in universities, startups, and early-stage investment groups. His startup operational experience includes both healthcare and bio-based renewable fuels. He was trained with a PhD in Physics from Carnegie Mellon University and an MBA from the University of Chicago Booth School of Business.

Jacob Segil, PhD

Venture Partner

Jacob is a Research Assistant Professor in Mechanical Engineering as well as the Managing Director of the Center for Translational Research at University of Colorado Boulder. He is a Research Healthcare Scientist in the Rehabilitation Research and Development service in the Department of Veterans Affairs. Jacob researches neural interfaces, prosthetic devices, and artificial sensory feedback systems. He has published 16 peer-reviewed scientific articles, holds 6 patents, and has founded three companies focusing on medical device development.

marta new, PhD, mba

Strategic Advisor

Marta is a founder and CEO of Radyus Research, a collaborative research organization specializing in preclinical drug development. She is an experienced drug developer and biotech investor having held positions at Agent Capital, Baxter Ventures, and Baxalta Ventures. Marta has spent most of her career translating early academic research into differentiated therapeutics, participating in building several successful academic spinouts and investing in over 20 biotech companies. She received her PhD in immunology and microbiology from the University of Illinois at Chicago and an MBA from Northwestern University.

our strategy →